CLOZAPINE TABLETS
국가: 캐나다
언어: 영어
출처: Health Canada
제품 특성 요약
(SPC)
11-10-2018
이 제품에 대한 일부 문서는 현재 사용할 수 없습니다. 고객 서비스에 요청을 보내면 가능한 빨리 알려 드리겠습니다.
요청을 보내십시오.
요청을 보내십시오.
유효 성분:
CLOZAPINE
제공처:
INNOMAR STRATEGIES INC.
ATC 코드:
N05AH02
INN (International Name):
CLOZAPINE
복용량:
25MG
약제 형태:
TABLET
구성:
CLOZAPINE 25MG
관리 경로:
ORAL
패키지 단위:
100
처방전 유형:
Prescription
치료 영역:
ATYPICAL ANTIPSYCHOTICS
제품 요약:
Active ingredient group (AIG) number: 0122583001; AHFS:
승인 상태:
APPROVED
승인 날짜:
2018-10-11
제품 특성 요약
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
Clozapine Tablets
25 mg and 100 mg
House Standard
Antipsychotic Agent
Innomar Strategies Inc. DATE OF REVISION:
3470 Superior Court October 11, 2018
Oakville, Ontario
L6L 0C4
Control No.: 219938
_Product Monograph _
_August 2018 _
_Page 2 of 57_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
............................................................... 3
SUMMARY PRODUCT INFORMATION
.........................................................................
3
INDICATIONS AND CLINICAL USE
...............................................................................
3
CONTRAINDICATIONS
..................................................................................................
5
WARNINGS AND PRECAUTIONS
.................................................................................
5
ADVERSE REACTIONS
...............................................................................................
21
DRUG INTERACTIONS
................................................................................................
28
DOSAGE AND ADMINISTRATION
...............................................................................
29
OVERDOSAGE
............................................................................................................
33
ACTION AND CLINICAL PHARMACOLOGY
................................................................ 35
STORAGE AND STABILITY
.........................................................................................
36
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................... 36
PART II: SCIENTIFIC INFORMATION
....................................................................................
38
PHARMACEUTICAL INFORMATION
...........................................................................
38
CLINICAL TRIALS
........................................................................................................
39
DETAILED PHARMACOLOGY
...........................
전체 문서 읽기
